Controversies and unresolved issues in tuberculosis prevention and control: A low-burden-country perspective

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Abubakar, Ibrahim ^a,b   Stagg, Helen R ^a   Cohen, Ted ^c   Mangtani, Punam ^d   Rodrigues, Laura C ^d   Pimpin, Laura ^a   Watson, John M ^a   Squire, S Bertel ^e   Zumla, Alimuddin ^e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; RIFAMPICIN; RIFAPENTINE;

COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG RESEARCH; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; IMMIGRANT; IMMUNIZATION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MASS SCREENING; MENINGITIS; MILIARY TUBERCULOSIS; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGEN LOAD; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PREVALENCE; PREVENTION AND CONTROL; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULIN TEST; TUBERCULOSIS; VACCINATION;

ANTITUBERCULAR AGENTS; BCG VACCINE; COMMUNICABLE DISEASE CONTROL; DEVELOPED COUNTRIES; HOMELESS PERSONS; HUMANS; INCIDENCE; POPULATION SURVEILLANCE; PRISONERS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SOCIOECONOMIC FACTORS; TRANSIENTS AND MIGRANTS; TUBERCULOSIS; URBAN POPULATION;

EID: 84860366378     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir886     Document Type: Review

References (66)

1. World Health Organization. Global tuberculosis control 2010. http://www.who.int/tb/publications/global-report/2010/en/index.html. Accessed 23 June 2011.
2. Hollo V, Amato-Gauci A, Kodmon C, Manissero D. Tuberculosis in the EU and EEA/EFTA countries: what is the latest data telling us? Euro Surveill 2009; 14. http://www.ncbi.nlm.nih.gov/pubmed/19317981. Accessed 16 April 2011.
3. Abubakar I, Lipman M, Anderson C, Davies P, Zumla A. Tuberculosis in the UKdtime to regain control. BMJ 2011; 343:d4281.
4. Winston C, Pratt R, Armstrong L, Navin T. Decrease in reported tuberculosis casesdUnited States, 2009. MMWRMorb Mortal Wkly Rep 2010; 59:289-94.
5. Pratt R, Price S, Miramontes R, Navin T, Abraham BK. Trends in tuberculosisdUnited States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:333-7.
6. Oren E, Winston CA, Pratt R, Robison VA, Narita M. Epidemiology of urban tuberculosis in the United States, 2000-2007. Am J Public Health 2011; 101:1256-63.
7. Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 2007; 62:667-71.
8. HaddadMB,Wilson TW, Ijaz K, Marks SM, MooreM. Tuberculosis and homelessness in the United States, 1994-2003. JAMA 2005; 293:2762-6.
9. Colijn C, Cohen T, Murray M. Emergent heterogeneity in declining tuberculosis epidemics. J Theor Biol 2007; 247:765-74.
10. Jit J, Stagg H, Aldridge R, White P, Abubakar I. Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. BMJ 2011; 343:d5376.
11. Geiter L, ed; Committee on the Elimination of Tuberculosis in the United States, Division of Health Promotion and Disease Prevention. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: The National Academies Press, 2000:292.
12. ECDC. Framework action plan to fight tuberculosis in the European Union. Stockholm: ECDC, 2008.
13. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York Citydturning the tide. N Engl J Med 1995; 333:229-33.
14. Wilson LG. The historical decline of tuberculosis in Europe and America: its causes and significance. J Hist Med Allied Sci 1990; 45:366-96.
15. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80.
16. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154-8.
17. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-45.
18. Fine PEM, Carneiro IA, Milstien J, Clements C. Issues relating to the use of BCG in immunization programmes: a discussion document. Geneva, Switzerland: World Health Organization, 1999.
19. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011; 8:e1001012.
20. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998; 2:200-7.
21. Aronson NE. Long-term efficacy of BCG vaccine in American Indians and AlaskaNatives: a 60-year follow-up study. JAMA2004; 291:2086-91.
22. Rodrigues L, Mangtani P, Abubakar I. How does the level of BCG vaccine protection against tuberculosis decline with time? BMJ 2011; 343:d5974.
23. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011; 11:633-40.
24. Schwartzman K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353:1008-20.
25. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; http://www.ncbi.nlm.nih.gov/pubmed/21562129. Accessed 24 September 2011.
26. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at the National Institute for Health and Clinical Excellence. Tuberculosis (CG117). Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, United Kingdom: Royal College of Physicians, 2011.
27. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11:435-44.
28. Pareek M, Abubakar I, White PJ, Garnett GP, Lalvani A. Tuberculosis screening of migrants to low tuberculosis burden nations: insights from evaluation of UK practice. Eur Respir J 2010. http://www.ncbi.nlm.nih. gov/pubmed/21071474. Accessed 16 April 2011.
29. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149:689-97.
30. Klinkenberg E, Manissero D, Semenza JC, Verver S. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009; 34:1180-9.
31. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25:1107-16.
32. Lowenthal P, Westenhouse J, Moore M, Posey DL, Watt JP, Flood J. Reduced importation of tuberculosis after the implementation of an enhanced pre-immigration screening protocol. Int J Tuberc Lung Dis 2011; 15:761-6.
33. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
34. Morgan M, Kalantri S, Flores L, PaiM. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:62.
35. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177-84.
36. Abubakar I, Story A, Lipman M, et al. Diagnostic accuracy of digital chest radiography for pulmonary tuberculosis in a UK urban population. Eur Respir J 2010; 35:689-92.
37. Markey AC, Forster SM, Mitchell R, Larson E, Smith H, Doré CJ. Suspected cases of pulmonary tuberculosis referred from port of entry into Great Britain, 1980-3. Br Med J (Clin Res Ed) 1986; 292:378.
38. Barnes PF, Verdegem TD, Vachon LA, Leedom JM, Overturf GD. Chest roentgenogram in pulmonary tuberculosis. New data on an old test. Chest 1988; 94:316-20.
39. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376-95.
40. Toman K, Frieden T. World Health Organization. Toman's tuberculosis: case detection, treatment, and monitoring: questions and answers. Geneva, Switzerland: World Health Organization, 2004: 358.
41. Burman WJ, Stone BL, Reves RR, et al. The incidence of false-positive cultures for Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997; 155:321-6.
42. Rajalahti I, Ruokonen EL, Kotomäki T, Sintonen H, Nieminen MM. Economic evaluation of the use of PCR assay in diagnosing pulmonary TB in a low-incidence area. Eur Respir J 2004; 23:446-51.
43. Liu Y, Weinberg MS, Ortega LS, Painter JA, Maloney SA. Overseas screening for tuberculosis in U.S.-bound immigrants and refugees. N Engl J Med 2009; 360:2406-15.
44. Abe C, Hirano K, Wada M, et al. Detection of Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and Gen-Probe Amplified Mycobacteriumtuberculosis Direct Test. J Clin Microbiol 1993; 31:3270-4.
45. Clarridge JE 3rd, Shawar RM, Shinnick TM, Plikaytis BB. Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory. J Clin Microbiol 1993; 31:2049-56.
46. Al Zahrani K, Al Jahdali H, Poirier L, René P, Gennaro ML, Menzies D. Accuracy and utility of commercially available amplification and serologic tests for the diagnosis of minimal pulmonary tuberculosis. AmJ Respir Crit Care Med 2000; 162:1323-9.
47. Mor Z, Lerman Y, Leventhal A. Pre-immigration screening process and pulmonary tuberculosis among Ethiopian migrants in Israel. Eur Respir J 2008; 32:413-8.
48. Harstad I, Jacobsen GW, Heldal E, et al. The role of entry screening in case finding of tuberculosis among asylum seekers in Norway. BMC Public Health 2010; 10:670.
49. de Vries G, van Hest RA, Richardus JH. Impact of mobile radiographic screening on tuberculosis among drug users and homeless persons. Am J Respir Crit Care Med 2007; 176:201-7.
50. Paolo WF Jr, Nosanchuk JD. Tuberculosis in New York City: recent lessons and a look ahead. Lancet Infect Dis 2004; 4:287-93.
51. Erkens C, Slump E, Kamphorst M, et al. Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants. Eur Respir J 2008; 32:153-61.
52. Alvarez GG, Gushulak B, Abu Rumman K, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis 2011; 11:3.
53. Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006; (2):CD005435.
54. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
55. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011; 12:15-22.
56. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54:49-55.
57. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155-66.
58. Ford CB, Lin PL, Chase MR, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43:482-6.
59. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey. Chest 1994; 106:431-4.
60. Trébucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997; 1:12-5.
61. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992; 41:61-71.
62. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998; 53:536-48.
63. Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis (Review). Cochrane Database Syst Rev 2009; (3):1-9.
64. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22:167-73.
65. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15:603-22.
66. Schaaf HS, Vermeulen HA, Gie RP, Beyers N, Donald PR. Evaluation of young children in household contact with adult multidrugresistant pulmonary tuberculosis cases. Pediatr Infect Dis J 1999; 18: 494-500.